International Maternal Adolescent AIDS Clinical Trials Group - Master Subcontract
Location(s): Uganda; Tanzania; Zambia; Zimbabwe; Botswana; South Africa; India; Thailand
An increasing number of HIV-infected children, globally, now have access to antiretroviral therapy (ART) and this number is increasing annually. In addition, the breadth of antiretroviral agents (ARV) agents has expanded resulting in longer survival and substantially improved quality of life. Pediatric HIV infection has been successfully transformed from a universally fatal infection of childhood to a manageable chronic disease requiring a lifetime of efficacious, tolerable and safe ART. The Primary Therapy Scientific Committee’s (PTSC) agenda aims to optimize antiretroviral management of children from infancy through adolescence and into young adulthood.
The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group is a cooperative group of institutions, investigators, and other collaborators organized for the purpose of evaluating potential therapies for HIV infection and its sequelae in the infant, pediatric, adolescent and pregnant women populations. IMPAACT was formed through a merger of investigators from the Pediatric AIDS Clinical Trials Group (PACTG) and the Perinatal Scientific Working Group of the HIV Prevention Trials Network (HPTN/HIVNET)